HMB-001, a novel bispecific antibody developed by Hemab Therapeutics, has shown promising results in Phase 1 clinical trials for treating Glanzmann Thrombasthenia.

Anixa Biosciences has initiated treatment for a fourth participant in its Phase 1 clinical trial for a new CAR-T cell therapy aimed at ovarian cancer.

Nuvalent has commenced the Phase 2 stage of the ALKOVE-1 clinical trial for NVL-655, a novel ALK-selective tyrosine kinase inhibitor (TKI).

Protagenic Therapeutics, Inc. has made progress in its clinical trial for a new brain peptide compound called PT00114.

The Phase 1b/2a AMARONE clinical trial's 12-week results indicate that Restoret, developed by Eyebiotech Limited, is well-tolerated in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).

Medicenna Therapeutics has initiated a Phase 1/2 clinical trial, known as the ABILITY-1 study, to assess the safety and efficacy of MDNA11, a modified version of interleukin-2 (IL-2).

A recent clinical study by Kiromic BioPharma, Inc. has shown positive results in the treatment of stage 4 metastatic non-small cell lung cancer (NSCLC) with their drug candidate, Deltacel™.

Carrick Therapeutics has initiated a Phase 1b/2 clinical trial to test the efficacy and safety of a combined treatment of samuraciclib (CT7001) and vepdegestrant (ARV-471) in patients.

AIM ImmunoTech Inc. has initiated a Phase 1b/2 clinical trial at Erasmus Medical Center for patients with advanced pancreatic cancer.

The European Medicines Agency (EMA) has approved the filings by Henlius and Organon for their biosimilar candidate HLX14 to Prolia® and Xgeva® (denosumab).

Kymera Therapeutics Unveils Novel Preclinical Findings for KT-621, an Oral STAT6 Degrader, at ATS Conference.

Scholar Rock begins Phase 2 EMBRAZE trial for Apitegromab and reveals new preclinical results for SRK-439 in treating obesity.